Scalable and Cost-Effective DNA Methylation Profiling to Accelerate Precision Medicine
| Reference number | |
| Coordinator | NEXUS Epigenomics AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | November 2025 - July 2026 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Important results from the project
The project met all technical and commercial goals. We delivered validated SOPs for four sample classes and robust analysis pipelines for MeTLAND® and HisTLAND®. Commercially, the emergence of HisTLAND® and the strategic targeting of core facilities drove our go-to-market success. Outreach yielded 18 customer meetings, multiple signed letters of intent and quote requests. By engaging key core facilities, we expanded our academic network, shipped early kits, and secured initial revenue.
Expected long term effects
NEXUS offers a versatile epigenomic platform. MeTLAND® and HisTLAND® share a sample workflow and analysis layer, making production highly cost-effective. Compatible DNA profiling methods enable large-scale biobank studies, accelerating biomarker discovery in diseases such as multiple sclerosis, where Sweden has the highest global incidence. Commercially, successfully engaging core facilities proved to be a highly scalable go-to-market strategy to reach European users without a large sales team.
Approach and implementation
The project was carried out across three core work packages: protocol development, analysis pipelines, and an Early Access Program. By actively integrating feedback from early pilot users, the team successfully refined the standard operating procedures (SOPs) and strategically adjusted the overall product focus.